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  INTRODUCTION 
 Virus-specific CD8     +       T cells contribute to the resolution of infec-
tion by a number of respiratory viruses. Following clearance of 
these viruses, the virus-specific T cells contract in numbers and 
a stable pool of memory cells is established that persists in the 
peripheral blood and lymphoid tissues. These memory T cells 
also accumulate in the pulmonary airways and parenchyma.  1  
Studies in mice and humans using sendai virus, influenza virus, 
and respiratory syncytial virus suggest that memory CD8      +       
T cells in the pulmonary airways may provide a first line of 
defense against secondary virus infections.  2 – 4  
  Vaccines that induce strong antiviral CD8      +        T-cell responses 
should confer protective immunity against such respiratory 
pathogens. Pulmonary immunization strategies have been 
developed that generate potent immune responses and protect 
against aerosolized challenge viruses.  5 – 7  For optimal protection 
against these pathogens, immunization should induce memory 
CD8      +        T cells that reside in the pulmonary compartment, sys-
temic effector-memory CD8      +       T cells that can rapidly migrate to 
the airways, and a reservoir of central memory CD8      +       T cells that 
can expand in numbers following exposure to virus.  8  Therefore, 
an effective vaccine against respiratory viruses should induce 
both pulmonary and systemic memory T-cell populations. 
 We have previously shown that pulmonary immunization with 
a plasmid DNA vaccine formulated with the cationic polymer 
polyethyleneimine (PEI; PEI-DNA) resulted in antigen expres-
sion in the lungs and the consequent generation of antigen-
specific CD8      +        T cells in the systemic circulation, the lung 
mucosa, and other mucosal compartments.  9   We have also 
demonstrated that systemic antigen-specific CD8      +        T  cells 
differentiated into effector-memory and central-memory 
populations following pulmonary PEI-DNA immunization. 
The present studies were initiated to further characterize the 
immune responses generated in the airways following pulmo-
nary PEI-DNA immunization and determine the contribution 
of PEI-DNA vaccine-induced CD8      +       T cells to protective immu-
nity against a respiratory viral challenge. We demonstrate that 
pulmonary PEI-DNA immunization induces antigen-specific 
CD8      +       T cells that persist in the airways and these resident cells 
confer protection against infection by respiratory viruses.     
  RESULTS   
  Pulmonary administration of plasmid DNA formulated with 
PEI induces persistent antigen-specific CD8        +         T cells in the 
lungs 
  Induction of antigen-specific CD8      +        T-cell responses in the 
lungs by pulmonary mucosal immunization may contribute 
to protection against inhaled pathogens. We therefore studied 
the effect of pulmonary DNA administration on the kinetics of 
CD8      +        T-cell responses in the systemic circulation and in the 
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 pulmonary compartment. For this pulmonary immunization, we 
formulated a plasmid DNA immunogen with the polymer PEI, 
as we previously showed that formulation with PEI improves 
plasmid DNA expression in the lungs and enhances pulmo-
nary vaccination-induced systemic CD8      +        T-cell  responses. 9  
This was not the case for immunization by the intramuscular 
(IM) route where formulation with PEI diminished plasmid 
DNA expression and did not enhance vaccine-induced CD8      +       
T-cell responses. Based on previous experiments, we determined 
that a pulmonary dose of 40     g plasmid DNA per mouse, given 
on two consecutive days, elicited the best responses (data not 
shown). We immunized Balb  /  c mice by the pulmonary route 
with 40         g HXBc2 gp120 DNA complexed with PEI and by the 
IM route with 40     g HXBc2 gp120 DNA solution. Vaccine elic-
ited CD8      +       T-cell responses were measured using the p18 / H-2D  d  
tetramer to detect cell populations specific for the 10-amino-
acid H-2D  d  -restricted dominant epitope of HXBc2 gp120.  10  
Peripheral blood mononuclear cell p18-specific CD8      +        T-cell 
responses were comparable in magnitude following pulmonary 
or IM DNA-gp120 immunizations (  Figure 1a  ). The kinetics of 
the p18-specific responses elicited by the two formulations and 
routes of administration were different, with peripheral blood 
p18-specific responses induced by pulmonary PEI-DNA-gp120 
immunization reaching peak levels more slowly than those 
induced by IM immunization. 
  We then assessed whether pulmonary DNA immunization 
could induce persistent immunity in the lungs. We isolated 
vaccine-elicited CD8      +        T cells from three anatomic compart-
ments: the mediastinal lymph nodes (MLN), the pulmonary 
airways, and the pulmonary parenchyma. To assess the persist-
ence of pulmonary cellular immunity, CD8      +        T-cell  responses 
were measured 6 weeks following immunization. p18-Specific 
CD8      +        T-cell responses were significantly higher in the MLN, 
lungs, and airways of the mice immunized by the pulmonary 
than by the IM route ( Figure 1b – d ). Pulmonary immunization 
with PEI-DNA-empty plasmid in conjunction with IM DNA-
gp120 did not increase the magnitude of p18-specific responses 
in the peripheral blood or in the pulmonary compartments 
compared with IM DNA-gp120 immunization (see 
  Supplementary Figure S1   online).  Therefore,  accumulation 
of antigen-specific CD8      +        T cells in the pulmonary compart-
ment following pulmonary administration of PEI-DNA is 
not an artifact resulting from the effects of PEI on the innate 
immune system or the recruitment of antigen-specific cells from 
the periphery. These findings establish that pulmonary PEI-
DNA immunization can induce CD8      +        T-cell immunity in the 
pulmonary compartment that persists for a prolonged period 
of  time.   
  Persistence of CD8        +         T cells in the lungs following pulmonary 
DNA immunization is not a consequence of ongoing antigen 
presentation or antigen-specific CD8        +         T-cell proliferation in 
the airways 
 We then explored the mechanism underlying the persistence of 
antigen-specific CD8      +       T cells in the lungs and airways following 
pulmonary PEI-DNA immunization. We first assessed how long 
plasmid DNA was present in the lungs following immunization 
as this would have a direct impact on the duration of   antigen 
IM Pulmonary
0
20
40
60
80
 
%
p
1
8
-
S
p
e
c
i
f
i
c
 
C
D
8
+
 
T
 
c
e
l
l
s
 
IM Pulmonary
0
2
4
6
8
10
 
%
p
1
8
-
S
p
e
c
i
f
i
c
 
C
D
8
+
 
T
 
c
e
l
l
s
 
IM Pulmonary 
0.0
0.5
1.0
1.5
 
%
p
1
8
-
S
p
e
c
i
f
i
c
 
C
D
8
+
 
T
 
c
e
l
l
s
Pulmonary
IM
Naive
0 1 02 03 04 05 0
Days postimmunization
0.0
0.2
0.4
0.6
0.8
1.0
a
 
%
p
1
8
-
S
p
e
c
i
f
i
c
 
C
D
8
+
 
T
 
c
e
l
l
s
MLN
*
BAL
*** ***
Lungs
b
cd
      Figure 1                        Effect of the route of immunization on systemic and mucosal p18-specific CD8        +         T-cell responses. Mice were immunized by the 
intramuscular (IM) route with 40        g of plasmid DNA expressing HIV-1 HXB2 gp120 protein or by the pulmonary route with 40        g of this DNA formulated 
with polyethyleneimine (PEI). (  a  ) Kinetics of the p18-specific CD8        +         T-cell response in the peripheral blood of immunized mice. p18-specific CD8        +         T-cell 
responses in (  b  ) mediastinal lymph nodes (MLN), (  c  ) pulmonary lymphocytes and (  d  ) broncho-alveolar lavage (BAL) lymphocytes of mice on day 42 
following IM immunization with DNA-gp120 or by the pulmonary route with PEI-DNA-gp120. Data represent means of 4  –  8 mice per group  ±  s.e.   158  VOLUME 6 NUMBER 1 | JANUARY 2013 | www.nature.com/mi
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presentation. PCR analysis of lungs from immunized mice did 
not detect plasmid DNA 3 weeks following immunization and 
showed that plasmid DNA was not retained in the lungs to 
account for the prolonged presence of CD8      +       T cells ( Figure 2a ). 
Next, we examined whether the persistence of antigen-specific 
CD8      +       T cells was a consequence of ongoing local antigen pres-
entation. To address this question, we evaluated the duration 
of antigen presentation in the draining lymph nodes of the 
lungs. We immunized B6-PL (Thy1.1      +      ) mice by the pulmonary 
route with PEI-DNA-OVA. Three and 6 weeks postimmuniza-
tion, CD8      +        T cells purified from naive OT-I (Thy1.2      +      )  mice 
were labeled with eFluor 670 and adoptively transferred by 
the intravenous route into the immunized mice. We reasoned 
that if presentation of the vaccine antigen was ongoing, the 
antigen-specific transferred cells would react by proliferating, 
and we would detect this proliferation by measuring eFluor 
670 fluorescence decay. As shown in   Figure 2b ,  antigen  pres-
entation to the donor OT-I cells in the MLN decreased over 
time, but could be detected for up to 6 weeks. This suggested 
that there was persistent presentation of antigen in the drain-
ing lymph nodes following pulmonary DNA immunization, 
long after the antigen was cleared.  9   As  antigen  presentation 
could also be mediated in the lung by resident DCs, we evalu-
ated whether there was persistent presentation in the airways 
and lung parenchyma. Labeled OT-I cells (Thy1.2      +      )  were 
transferred intratracheally to B6-PL (Thy1.1      +       ) mice and cell 
proliferation was measured as an indicator of antigen presen-
tation. We detected antigen presentation in the airways and 
lung parenchyma 10 days following immunization ( Figure 2c ); 
however, by day 21 antigen presentation was no longer detected 
in this anatomic compartment ( Figure 2d ). To directly evaluate 
antigen presentation by cells in the lung compartment, we used 
a major histocompatibility complex class I presentation assay. 
Single-cell suspensions from lungs of pulmonary immunized 
mice  were  depleted  of  CD4 / CD5 / CD8  and  co-cultured  with 
a T-cell hybridoma that secretes IL-2 upon recognition of the 
OVA CD8      +        T-cell  –  specific SIINFEKL peptide presented on 
antigen-presenting cells (APCs). This would directly meas-
ure whether SIINFEKL is still presented in the lung compart-
ment by APCs. There was no detectable antigen presentation 
in the lungs of pulmonary immunized mice 6 weeks follow-
ing immunization although APCs from those animals were 
capable of presenting when peptide was present (  Figure 2d ). 
This demonstrates that antigen presentation is not sustained in 
the lungs or airways long term. Phenotypic analysis of OVA-
specific CD8      +        T cells isolated from broncho-alveolar lavage 
(BAL) 6 weeks following immunization presented low expres-
sion of CD11a and CD103 (see   Supplementary Table S1  
online). As antigen-specific CD8      +        T cells lose CD11a when 
they reach the airways and CD103 is expressed during sustained 
antigen presentation, these findings support our observations 
of persistence of antigen-specific CD8      +        T cells in the airways 
in the absence of local ongoing antigen presentation. 
 The persistence of antigen-specific CD8      +       T cells in the airways 
following pulmonary immunization may also be a consequence 
of local cell proliferation. To assess local airway CD8      +       T-cell pro-
liferation, Balb / c mice were immunized by the  pulmonary route 
with PEI-DNA-gp120, and 3 or 6 weeks later eFluor 670 was 
applied directly to the airways. Four days following this regional 
staining, proliferation of antigen-specific CD8      +        T cells was 
measured. We found that airway CD8      +        T cells did not expand 
3 and 6 weeks following immunization. Rather, they underwent 
only 1 – 2 rounds of proliferation. This could be a consequence of 
local T-cell turnover rather than clonal expansion (  Figure 2e ). 
The cell division of airway antigen-specific CD8      +        T cells was 
further evaluated using the 5-ethynyl-2   -deoxyuridine  (EdU) 
assay that directly measures DNA synthesis. Airway CD8      +       
T cells from mice infected intranasally with vaccinia virus 
              Figure 2                        Persistence of pulmonary CD8        +         T cells is independent of the duration of antigen presentation in the airways and lungs or local T-cell 
proliferation. (  a  ) Lungs were harvested from B6 mice 2 days and 3 weeks post pulmonary PEI-DNA-OVA immunization and plasmid DNA isolated from 
the tissue. The OVA sequence was amplified from plasmid DNA by PCR. The plasmid DNA-OVA used for immunization served as positive control (pos ctr) 
while plasmid DNA without the OVA insert served as the negative control (neg ctr). (  b  ) B6.PL (Thy 1.1        +        ) mice were immunized by the pulmonary route with 
PEI-DNA-OVA and 21 and 42 days later, received adoptively transferred labeled OT-I cells (Thy 1.2        +        ) by intravenous injection. The dilution of eFluor 670 
in donor Thy1.2        +         tetramer        +         CD8        +         T cells was evaluated in mediastinal lymph nodes (MLN) of the immunized mice 4 days post transfer. Representative 
histograms show the average percentages  ±  s.e. of proliferating Thy1.2        +         tetramer        +         CD8        +         T cells (3  –  4 mice per group). (  c  ) Labeled OT-I cells (Thy 1.2        +        ) were 
adoptively transferred to the airway lumen of B6.PL mice (Thy 1.1        +        ). One day later, mice were immunized by the pulmonary route with PEI-DNA-OVA, and 
10 days later, donor tetramer-binding CD8        +         T cells were isolated from the BAL and lungs, and evaluated for the dilution of eFluor 670 staining. (  d  ) B6-PL 
(Thy 1.1        +        ) mice were immunized by the pulmonary route with PEI-DNA-OVA and 21 days later received adoptively transferred labeled OT-I cells (Thy 1.2        +        ) 
in their airway lumens. The dilution of eFluor 670 in donor Thy1.2        +         tetramer        +         CD8        +         T cells was evaluated 4 days later in BAL and lungs. Representative 
histograms show the average percentages  ±  s.e. of proliferating Thy1.2        +         tetramer        +         CD8        +         T cells (6  –  8 mice per group). Local antigen presentation was 
also evaluated in lungs of B6 mice immunized by the pulmonary route with PEI-DNA-OVA. Lungs were harvested 6 weeks following immunization and 
co-cultured with the RF.33.70 hybridoma overnight. The levels of IL-2 secretion from the RF33.70 hybridoma in response to SIINFEKL presentation were 
determined using a mouse IL-2 enzyme-linked immunosorbent assay. Bars represent the average  ±  s.e. of secreted IL-2 (3 mice per group). (  e  ) Mice were 
inoculated by the pulmonary route with PEI-DNA-gp120, and 3 and 6 weeks later eFluor 670 was applied to the airways to stain local resident T cells. Four 
days later, the dilution of eFluor 670 staining of tetramer        +         CD8        +         T cells in the BAL was assessed. Histograms representative of 3  –  8 mice per time point 
are shown. Proliferation of antigen-specific CD8        +         T cells was also evaluated in the BAL of immunized Balb  /  c mice 6 weeks following pulmonary PEI-DNA-
gp120 immunization. Mice were injected with 250        g 5-ethynyl-2    -deoxyuridine (EdU) intraperitoneally 12    h before sacrifice. Cells isolated from the BAL 
were stained with monoclonal antibodies to CD4 and CD8, fixed, permeabilized, and EdU detected with the Alexa Fluor 647 Click-iT EdU flow cytometry 
assay kit. Representative plot show the average percentages  ±  s.e. of EdU incorporation by BAL CD8        +         T cells (3 mice per group). BAL CD8        +         T cells from 
mice infected intranasally with rVac-gp160 were used as a positive control for local proliferation. APC, antigen-presenting cells; BAL, broncho-alveolar 
lavage; ctr, control; IL-2, interleukin 2; pep, peptide; PEI-DNA-OVA, polyethyleneimine-DNA-Ovalbumin complexes.   MucosalImmunology | VOLUME 6 NUMBER 1 | JANUARY 2013   159
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proliferated 6 days following infection and were used as a posi-
tive control for the assay. Airway CD8      +       T cells from pulmonary 
PEI-DNA-gp120 immunized mice did not show significant levels 
of proliferation at 6 weeks following immunization. These find-
ings are consistent with the conclusion that antigen presentation 
is not sustained in the lungs or airways long term. Collectively, 
these data suggest that the persistence of antigen-specific CD8      +       
T cells in the airways is not due to ongoing antigen presenta-
tion in the airways or local expansion of resident cells; rather, 
this population is either comprised of long-lived tissue-resident 
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CD8      +        cells or is maintained by persistent antigen presentation 
in the draining MLN.     
  Pulmonary PEI-DNA immunization confers immune 
protection against a respiratory virus challenge 
 We then determined whether a single pulmonary administration 
of PEI-DNA generated protective immunity against an upper 
airway viral infection. Mice were immunized by the pulmonary 
route with PEI-DNA-gp120 and challenged by the intranasal 
route 6 weeks after immunization with 2 × 10  6  PFU rVac-gp160, 
10 times the LD  50  of this virus in Balb / c mice ( Figure 3a ). Lungs 
and ovaries from challenged mice were harvested and analyzed 
for viral load using a vaccinia virus plaque assay. As shown in 
  Figure 3b  , viral titers in the lungs and ovaries of these immu-
nized mice were significantly lower than the titers in lungs and 
ovaries of the challenged naive mice (  P     <    0.001).  To  determine 
whether viral load was associated with the consequences of 
infection, we monitored the survival following challenge of naive 
mice and the mice immunized by IM and pulmonary routes. 
Unvaccinated mice and mice immunized by the IM route mice 
succumbed to infection 8 days following challenge, whereas 
100 %  of the mice immunized by the pulmonary route were pro-
tected against intranasal recombinant vaccinia virus challenge 
(  Figure 3c  ). These data demonstrate that while immunization 
by the IM route induces no protective immunity against this 
challenge, immunization with a single pulmonary inoculation 
of PEI-DNA provides protection against a lethal intranasal 
challenge with vaccinia virus.     
  Protective immunity following PEI-DNA immunization by the 
pulmonary route is mediated by CD8        +         T cells 
  Pulmonary T cells can have a key role in protective immunity 
against pathogens by eliminating the pathogens at the site of 
entry, before they disseminate throughout the body. In a pre-
vious study, we were able to recover antigen-specific CD8      +       
T cells from the pulmonary airways long after antigen expression 
from the DNA vaccine was no longer detectable.  9   We  therefore 
hypothesized that these cells contributed to the protection we 
observed following pulmonary immunization. To test this hypoth-
esis, mice were immunized by the pulmonary route with PEI-DNA-
gp120 and 6 weeks later their airway CD8      +        T cells were depleted 
using a monoclonal anti-CD8 antibody administered by the pul-
monary route. Two days following anti-CD8 antibody treatment, 
mice were intranasally challenged with 2  ×  10  6   PFU rVac-gp160, 
and 5 days later viral load was analyzed in their lungs and ovaries 
(  Figure 4a ). To confirm the adequacy of the CD8      +       T-cell depletion, 
BAL from the immunized mice that were treated with the anti-
CD8 monoclonal antibody were analyzed for the presence of cells 
stained with an anti-CD8 antibody (  Figure 4b  ). No CD8      +        cells 
were found, indicating that administration of the depleting mono-
clonal antibody to the airways results in efficient depletion of CD8      +       
T cells from the pulmonary compartment (  Figure 4b   and data 
not shown). Viral loads in the lungs and ovaries of CD8      +        T-cell –
 depleted, immunized mice were comparable with those of unvac-
cinated mice (  Figure 4c  ). These findings provide evidence that 
protection against intranasal recombinant vaccinia virus 
challenge following pulmonary PEI-DNA immunization is medi-
ated by CD8      +       T cells.    
  Resident pulmonary CD8        +         T cells can protect mice against 
an intranasal viral challenge independent of peripheral T-cell 
recruitment 
  The present findings indicated that pulmonary PEI-DNA 
immunization generated protective immunity against an 
intranasal viral challenge, and this protection was associ-
ated with the persistence of CD8      +        T cells in the pulmonary 
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        Figure 3                        Pulmonary PEI-DNA immunization protects against intranasal vaccinia virus challenge. (  a  ) Mice were primed by intramuscular (IM) 
inoculation with 40        g DNA-gp120 or pulmonary inoculation of PEI-DNA-gp120 and challenged 6 weeks later by intranasal instillation of a lethal dose 
(2  ×  10  6   PFU) of vaccinia virus-gp160. Protective immunity was monitored by evaluating (  b  ) viral titers in the lungs and ovaries, and (  c  ) mouse survival. 
Statistically significant differences between groups were determined using the Student  ’  s   t  -test (  *    *    *    P        <      0.001). Data represent means of 4  –  9 mice per 
group  ±  s.e. PEI, polyethyleneimine; PFU, plaque-forming units.   MucosalImmunology | VOLUME 6 NUMBER 1 | JANUARY 2013   161
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compartment long after immunization. We sought to determine 
whether protection against an intranasal recombinant vaccinia 
virus infection was solely mediated by airways resident CD8      +       
T cells, or whether recruitment of peripheral T cells into the 
lungs is necessary for clearing the infection. To explore this 
issue, we used FTY720 (Fingolimod) treatment, which has been 
shown to block T-cell trafficking from both lymphoid organs 
and non-lymphoid tissues.  11   This treatment allowed us to iso-
late the CD8      +       T cells in the airways and evaluate whether they 
were sufficient to protect against infection in the absence of an 
influx of T cells from the periphery and the lung parenchyma. 
Balb / c mice were immunized by the pulmonary route with PEI-
DNA-gp120 and 6 weeks later were injected with FTY720 to 
block lymphocyte trafficking (  Figure 5a  ). One day following 
FTY720 administration, mice were challenged by the intranasal 
route with 2 × 10 6  PFU rVac-gp160, and lungs and ovaries were 
harvested 5 days later for viral load analysis. To assess the drug ’ s 
effect, we measured the levels of circulating T cells and anti-
gen-specific CD8      +       T cells in the mucosal compartment before 
challenge. FTY720 administration resulted in a peripheral 
blood lymphopenia, consistent with an efficacious treatment 
(  Figure 5b ). There were no significant differences in the num-
bers of tetramer-positive CD8      +       T cells in the lungs, MLN, and 
BAL following FTY720 treatment ( Figure 5c ). Despite the treat-
ment-induced blockade of the peripheral T-cell supply, immu-
nized animals were protected against intranasal recombinant 
vaccinia virus challenge (  Figure 5d  ). The viral loads in the 
lungs and ovaries of mice immunized by the pulmonary route 
with PEI-DNA that were treated or not treated with FTY720 
were significantly lower than the viral loads in these organs in 
unvaccinated mice. Importantly, there were no significant dif-
ferences in the viral titers of the immunized mice that received 
the FTY720 treatment and the mice that did not receive the 
treatment. Importantly, the numbers of tetramer-specific CD8      +       
T cells in the BAL following vaccinia virus infection remained 
similar to what they were before infection, indicating that there 
was no local recruitment of cells from the lung parenchyma 
(  Figure 5c  ). These data suggest that antigen-specific CD8      +       
Naive Pulmonary
4
5
6
7
8
9
L
o
g
 
P
F
U
Naive Pulmonary
4
5
6
7
8
9
L
o
g
 
P
F
U
42 Days
a
5 Days 2 Days
Pulmonary PEI-gp120 
plasmid immunization
Pulmonary 
CD8+ T-cell
depletion
Intranasal vaccinia 
virus-gp160
challenge
Plaque assay
for lungs and 
ovaries
CD8+ T-cell depletion BAL
CD8
SSC
Lungs Ovaries
b
c
          Figure 4                        Protective immunity following pulmonary PEI-DNA-gp120 immunization is mediated by CD8        +         T cells. (  a  ) Mice were inoculated by the 
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T cells in the airways induced by pulmonary PEI-DNA immu-
nization can mediate immune protection against a viral chal-
lenge without requiring recruitment of additional lymphocytes 
from the periphery.     
  Antigen-specific CD8        +         T cells induced by pulmonary 
PEI-DNA immunization protect against an influenza virus 
challenge 
  Finally, we assessed the protection conferred by pulmonary 
immunization with PEI-DNA against influenza virus. We 
immunized mice by the pulmonary route with PEI-DNA-OVA, 
and 6 weeks later challenged the vaccinated mice by the intra-
nasal route with 10  5  EID 50  of PR8 influenza virus encoding the 
OVA  257 – 264   (SIINFEKL)  epitope  ( Figure 6a ).  This  challenge 
system allowed us to assess protective immunity against influenza 
and also determine whether the protection was CD8      +        T-cell 
mediated, as only SIINFEKL-specific CD8      +        T cells could con-
tribute to protection against infection with this recombinant 
virus. As shown in  Figure 6b , the influenza virus challenge was 
lethal in unvaccinated mice. Likewise, the challenge was lethal 
in all mice immunized by the IM route. However, we observed 
significant protection in the mice immunized by the pulmo-
nary route after challenge with influenza virus with a 71  %   sur-
vival rate. Mice immunized by the pulmonary route lost 25 %  of 
their body weight by day 7 post challenge, but regained weight 
back to 94  %   of their starting weight by day 22 (  Figure 6c ). 
These findings provide further evidence to support the poten-
tial utility of pulmonary PEI-DNA immunization for induc-
ing CD8      +        T-cell immune responses for protection against 
respiratory  pathogens.    
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  DISCUSSION 
 In these studies, we show that pulmonary PEI-DNA immuniza-
tion induced protective immunity against viral pathogens that 
initiate infections via the pulmonary route. This protection was 
mediated by long-lived memory CD8      +       T-cell populations resid-
ing within the airways. These persistent effector-memory CD8      +       
T cells are similar to those observed in the airways after influ-
enza and respiratory syncytial virus infections are resolved.  2,12  
Although their mechanism of action has not been clearly 
defined, memory CD8      +       T cells in the airways have been shown 
to be poorly cytolytic and mediate protective cellular immunity 
by controlling viral load during the early stages of infection, pos-
sibly through secretion of cytokines such as interferon-   . 13,14  
 Although the persistence of pathogen-specific CD8      +       T cells in 
the airways has been shown following a number of pulmonary 
infections and vaccination,  2,4,15  the mechanisms responsible for 
their maintenance in the airways has been a subject of much 
debate and investigation. Persistence of memory CD8      +        T cells 
in the airways could be a consequence of prolonged local  antigen 
presentation, local homeostatic proliferation, or recruitment of 
memory cells from the circulation.  16  We sought to define which 
mechanisms are responsible for the persistence of antigen-
specific CD8      +       T cells in the airways following pulmonary PEI-
DNA immunization. We showed that despite a brief duration 
of vaccine antigen presentation in the airways, we detected 
prolonged antigen presentation in draining lymph nodes. This 
finding is consistent with the presence of residual antigen in the 
draining lymph nodes, even though we could not detect antigen 
expression for more than 5 days following pulmonary PEI-DNA 
delivery using the  in vivo  imaging system (IVIS) technology  9  or 
after 3 weeks using PCR. In fact, persistent antigen presentation 
has been shown following acute viral infections and is thought 
to contribute to sustained immune responses.  17,18  The priming 
location of the antigen-specific CD8      +        T cells could also affect 
the maintenance of these cells in the airways and pulmonary-
primed memory CD8      +        T cells can be reactivated by residual 
antigen in the MLN and are preferentially recruited to the air-
ways.  19   Our data suggests that processed T-cell antigens in the 
MLN are retained following pulmonary PEI-DNA immuniza-
tion without plasmid DNA expression, although it is possible 
that small amounts of plasmid DNA (below the limits of detec-
tion in our assays) have been retained in some tissues or cells 
such as macrophages and dendritic cells. We did not observe 
the proliferation of antigen-specific (OT-I) CD8      +       T cells when 
adoptively transferred at 6 weeks following pulmonary PEI-
DNA immunization. Rather, we observed 1  –  2 cycles of CD8      +       
T-cell proliferation, consistent with homeostatic turnover of 
these cells. This type of proliferation has been described in res-
piratory virus-induced CD8      +       T cells and is a well-characterized 
mechanism for the maintenance of peripheral T-cell memory.  20  
This finding highlights the difference between immunization 
using plasmid DNA and recombinant adenovirus constructs, 
as the latter was recently shown to generate renewable airway 
luminal memory CD8      +        T cells.  21  
  The presence of memory CD8      +        T cells in tissues at sites of 
pathogen entry can provide for an effective first line of defense 
against infections. Consistent with this idea, we observed sig-
nificantly lower viral loads in the lungs and ovaries of mice 
immunized with PEI-DNA via the pulmonary route than IM 
immunized and unimmunized mice. More importantly, the 
decrease in viral loads we observed translated into host pro-
tection; 100 %  of the animals immunized with PEI-DNA-gp120 
via the pulmonary route survived an intranasal challenge with 
a lethal dose of rVac-gp160, whereas unimmunized and IM 
immunized mice did not survive past day 8 post challenge. Our 
data indicates that memory CD8      +        T cells in pulmonary PEI-
DNA-immunized mice mediated this protection, presumably by 
limiting respiratory infection at the site of virus entry and block-
ing significant spread of the virus to systemic compartments, 
as suggested by the low viral titers in the ovaries. The protec-
tive efficacy of pulmonary immunization with PEI-DNA was 
also confirmed in an influenza virus challenge model in which 
pulmonary PEI-DNA immunized mice had higher survival 
rates following infection than unimmunized and IM immu-
nized mice. It was reported that memory T cells in the lungs are 
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exclusively of an effector-memory phenotype both during and 
following infection, and can be effective at protecting the lung 
mucosa from infection.  22,23  Our findings suggest that PEI-DNA 
complexes are an efficient immunization platform for generating 
sustainable memory CD8      +        T cells that are protective against 
respiratory virus infections. 
  Having demonstrated that pulmonary PEI-DNA immuniza-
tion generated CD8      +        T cells in the pulmonary compartment 
that can mediate protection against respiratory viral challenge, 
we sought to establish whether those cells were sufficient for the 
observed protection, or if recruitment of effector memory CD8      +       
T cells from the circulation was required. When systemic T-cell 
trafficking was blocked by FTY720 treatment, and inhibited 
recruitment of lung-resident antigen-specific CD8      +       T cells into 
the airways ( Figure 5 ), we observed no diminution in immune 
protection against intranasal rVac-gp160 challenge in mice that 
received PEI-DNA via the pulmonary route. These data suggest 
that vaccine-induced airways memory CD8      +        T cells have an 
immediate effector function and are present in the airways in 
sufficient numbers to protect against a pulmonary viral infec-
tion without cell recruitment from the circulation. These data 
also demonstrate that a non-viral vector can generate effective 
effector CD8      +        T cells in the pulmonary compartment that can 
mediate immune protection against pulmonary viral infection 
long after antigen is cleared. 
 Data suggest that DNA vaccines can be formulated in novel ways 
to maximize the magnitude and duration of antigen expression 
  in vivo . PEI has been shown to be an efficient and well-tolerated 
transfection agent for local and systemic administration.  24 – 26  We 
previously showed that although PEI enhanced DNA expression 
in the lungs following pulmonary administration, gene expression 
was short-lived.  9   Despite this brief duration of antigen expres-
sion in the lungs, this study shows that it was sufficient to induce 
protective immunity against respiratory viral challenge. 
  In the present study, we used a non-invasive pulmonary 
aerosol administration of the vaccine immunogen and formu-
lated the DNA vaccine with the cationic polymer PEI. There 
is an ongoing debate in the literature as to whether direct lung 
immunization is superior to intranasal immunization. The latter 
vaccine delivery approach has been extensively studied, is an 
easy method of vaccine delivery, and is clinically approved for 
influenza immunization in humans. Many studies have shown 
that intranasal immunization protects against infections.  21,27,28  
However, a recent study by Song   et al.  29   has demonstrated that 
intranasal delivery of recombinant adenovirus is less effec-
tive in generating humoral and cellular immune responses in 
the pulmonary airways of nonhuman primates than aerosol 
delivery. The results of the present study complements those 
experiments in arguing that depositing a vaccine immunogen 
directly in the lungs may be the most efficient way to induce 
protective immunity in the pulmonary mucosa.     
  METHODS         
  DNA vectors   .    The  codon-optimized  HIV-1  HXB2   env   and the OVA 
genes were cloned separately into the VRC vector (DNA-gp120 and 
DNA-OVA, respectively). The empty VRC vector was provided by 
Dr G. Nabel (Vaccine Research Center, National Institute of Allergy and 
Infectious Diseases, National Institutes of Health). Plasmids were pre-
pared using the Endo-free plasmid Giga kit (QIAGEN, Valencia, CA) 
and had endotoxin levels     <    0.1   EU     g     −     1  DNA.   
  Preparation of PEI-DNA complexes   .    Plasmid  DNA  was  complexed 
with  in vivo -jetPEI (Polyplus transfection, Illkirch, France) according to 
the  manufacturer ’ s  guidelines.  Specifically,  0.7   mg   ml     −     1   plasmid  DNA 
solution in 5 %  glucose was mixed with jetPEI solution to achieve a final 
DNA concentration of 0.4   mg   ml     −     1  and an N / P ratio of 7.5. The mixture 
was incubated for at least 30     min at room temperature in order for the 
complexes to form before being injected into the mice.    
  Mice and immunizations   .    Balb / c  female  mice,  8 – 12-weeks  old,  were 
purchased from Charles River Laboratories (Wilmington, MA). C57BL / 6 
(B6) mice, B6.PL mice carrying the Thy1.1 allele, and transgenic OT-I 
mice were purchased from the Jackson Laboratory (Bar Harbor, ME) and 
maintained under specific pathogen-free conditions. Research on mice 
was approved by the Beth Israel Deaconess Institutional Animal Care and 
Use Committee. Mice were immunized IM with 40     g of DNA in solution 
in a 100-   l  total  injection  volume  (50      l delivered into each quadriceps 
muscle). Non-invasive aerosol applications were performed using the 
technique described by Bivas-Benita   et al.  30   In short, 50        l  formulation 
consisting of 40         g DNA complexed to jetPEI was sprayed directly into 
the airways of mice with the Penn-Century MicroSprayer (Penn-Century, 
Wyndmoor, PA). Identical procedures were used for the gp120 and OVA-
expressing plasmids.    
  Lymphocyte isolation for tetramer and phenotypic analysis of T cells   .  
  Blood samples from individual mice were collected in RPMI 1640 supple-
mented with 40   U   ml     −     1  heparin and peripheral blood mononuclear cells 
were isolated by density gradient centrifugation using Lympholyte-M 
(Cedarlane, Burlington, NC). Cells collected from the gradient inter-
face were washed with phosphate-buffered saline (PBS) containing 2  %   
fetal bovine serum and stained at room temperature for 20     min with 
phycoerythrin-conjugated H-2D  d  / p18 or SIINFEKL tetramer. Cells were 
then stained with anti-CD3e-APC-Cy7 (145-2C11) and anti-CD8a-
PerCP-Cy5.5 (53-6.7) from BD Biosciences (San Jose, CA) at room 
temperature for an additional 15     min. Following staining, cells were 
washed once and fixed with PBS containing 2 %  paraformaldehyde. 
  Lungs and MLN were removed aseptically and the airway luminal 
cells were removed from the lungs by four consecutive BALs through a 
cannula in a volume of 2     ml PBS to ensure efficient recovery. Following 
the lavage, lungs and MLN were cut into small pieces using straight scis-
sors  and  incubated  with  1.33   mg   ml     −     1   collagenase-D  and  0.2   mg   ml     −     1  
DNase (Roche, Indianapolis, IN) in HBSS for 1 hour and 30   min, respec-
tively, at 37    ° C with vigorous shaking. Tissue fragments were then crushed 
through a 70-    m pore size filter and cells were washed once. Lung cells 
were resuspended in 40 %  Percoll (Sigma-Aldrich, St Louis, MO), layered 
over 67 %  Percoll, and centrifuged at 1,900   r.p.m. for 25   min. The lympho-
cytes were present in the interface between the two Percoll layers. For 
tissue tetramer staining, lymphocytes were collected from the gradient 
interface, washed, and stained as described above for blood samples. MLN 
samples were washed twice after the filtration step and similarly stained. 
Samples were analyzed using an LSR II flow cytometer (BD Biosciences, 
San Jose, CA) and FlowJo software (Tree Star, Ashland, OR).    
  PCR analysis of plasmid DNA   .    B6  mice  were  pulmonary  immunized 
with PEI-DNA-OVA and DNA was isolated from their lungs using the 
Qiagen DNeasy kit (Qiagen, Valencia, CA). For the PCR reaction, the 
forward primer (5   -CTCAAAAGACA GCGGCCGCGCC ACCATGG
GCTCCATCGGCGCAGCAAGCA) and the reverse primer (5  -AGCT
TTC GGATCC TTAAGGGGAAACACATCTGCCAAAGAAGAGAA
CGGCG) were used with the Platinum PCR SuperMix High Fidelity for 
PCR amplification (Invitrogen, Grand Island, NY). The plasmid DNA-
OVA used for immunization served as positive control for the reaction. MucosalImmunology | VOLUME 6 NUMBER 1 | JANUARY 2013   165
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Each reaction consisted of 45     l Platinum PCR SuperMix High Fidelity, 
200   n m  final concentration of each primer solution, and 200   ng genomic 
DNA template. PCR products were then subjected to agarose gel elec-
trophoresis and 2-log DNA ladder was used to determine the amplicon ’ s 
mass (New England BioLabs, Ipswich, MA).    
    In vivo   antigen presentation assays   .    Lymphocytes  from  spleens  and 
lymph nodes of OT-I mice were washed with PBS and incubated with 
an equal volume of 10           m   eFluor 670 (eBioscience, San Diego, CA) in 
PBS for 10     min at 37       °  C, at a final concentration of 5         m .  To  quench  the 
label, ice-cold RPMI 1640 complete medium was added, incubated on 
ice for 5     min, and then cells were washed twice with PBS. To evaluate 
antigen presentation in MLN, 5  ×  10  6   labeled cells in 200         l were adop-
tively transferred into B6.PL mice by tail vein injection. For pulmonary 
evaluation of antigen presentation, cells were resuspended in 50        l  PBS 
and instilled intratracheally in B6.PL mice. BAL, lungs, and MLN were 
harvested at different time points and the level of eFluor 670 dilution 
was determined by flow cytometry using Live  /  Dead fixable aqua dead-
cell stain (Invitrogen), specific phycoerythrin-labeled tetramers, anti-
CD3e-APC-Cy7 (145-2C11; BD Biosciences), anti-CD8a-PerCP-Cy5.5 
(53-6.7; BD Biosciences), and anti-Thy1.2-eFluor 450 (53-2.1; eBio-
science). To assess direct antigen presentation in the lung, lungs were 
removed and digested as described above. Single-cell suspensions 
were depleted of T cells by MACS separation using CD4, CD5 and 
CD8 MicroBeads according to the manufacturer  ’  s guidelines (Miltenyi 
Biotec, Auburn, CA). RF33.70 hybridoma cells (a gift from Dr K. Rock, 
University of Massachusetts, Worcester, MA), which produce IL-2 upon 
specific recognition of SIINFEKL presented by APCs, were co-cultured 
for 24   h with lung APCs in a 96-well plate (5 × 10  4  cells / well). Supernatants 
were collected and IL-2 levels were determined by the OptEIA mouse 
IL-2 ELISA kit (BD Biosciences, San Jose, CA) according to the manu-
facturer ’ s instructions.   
    In vivo   airway lymphocyte proliferation   .   For luminal staining of anti-
gen-specific CD8      +       T cells, a 25   m m  solution of eFluor 670 was prepared 
in dimethyl sulfoxide. This stock solution was further diluted with 5  %   
glucose  solution  to  a  final  concentration  of  2   m m .  Mice  immunized 
with PEI-DNA-gp120 by the pulmonary route were administered 50        l 
of the 2     m  m   eFluor 670 solution using the same non-invasive applica-
tion method we used for immunization, and eFluor 670 dilution was 
determined 4 days later. Proliferation was further evaluated using the 
thymidine analog EdU. Pulmonary immunized animals were adminis-
tered 250     g of EdU in PBS intraperitoneally. Mice infected intranasally 
with replication-competent NYCBH strain vaccinia virus expressing 
HIV-1 B10 (rVac-gp160) were used as positive control. One day after 
EdU administration, mice were killed and cells isolated from BAL. Cells 
were stained with anti-CD8a-PerCP-Cy5.5 (53-6.7; BD Biosciences) 
and evaluated for incorporated EdU using the Alexa Fluor 647 Click-iT 
EdU flow cytometry assay kit according to the manufacturer ’ s guidelines 
(Invitrogen).   
    In vivo   CD8      +        T-cell depletion   .     C D 8      +        T-cell depletion in mice was 
accomplished with sterile-purified rat IgG2b anti-mouse CD8 mono-
clonal antibody (YTS 169.4, Bio-X-cell; West Lebanon, NH). In all, 50     l 
of  a  2   mg   ml     −     1   antibody solution were sprayed in the lungs of mice by 
non-invasive pulmonary administration 6 weeks following their immu-
nization. Two days following this treatment, mice were challenged 
intranasally with 2  ×  10  6    pfu  rVac-gp160  and  viral  titers  were  evaluated 
5 days post challenge in lungs and ovaries using plaque forming assays 
on CV-1 cells.    
  Blockage of peripheral T-cell recruitment   .    Immunized  mice  were 
injected i.p. with 200        l  of  0.4   mg   ml     −     1   FTY720  solution  (Cayman 
Chemical, Ann Arbor, MI) to block T-cell recruitment to the lungs. 
The efficacy of the treatment was confirmed by measuring CD3      +       
lymphocytes in the peripheral blood of the mice.    
  Recombinant vaccinia virus challenge   .    Groups  of  mice  were  chal-
lenged 6 weeks after a plasmid DNA immunization with replication-
competent NYCBH strain vaccinia virus expressing HIV-1 B10 (rVac-
gp160). Mice were anesthetized by intraperitoneal injection with a 
ketamine  (100   mg   kg     −     1 ) / xylazine  (10   mg   kg     −     1 )  mixture  and  2 × 10 6    p f u  
rVac-gp160 (10  ×  LD50) was instilled intranasally. Infected mice were 
monitored for survival and viral titers in the lungs and ovaries. For the 
evaluation of viral titers, mice were sacrificed 5 days following vaccinia 
virus challenge and their lungs and ovaries were harvested and frozen 
at      −    80    ° C  until  analysis.  A  day  before  the  assay,  tissues  were  thawed, 
homogenized in 100   m m  Tris buffer, pH    =    8, and frozen again overnight. 
On the day of the assay the cells were sonicated for 2   min and viral titers 
were evaluated by plaque forming assay on CV-1 cells. Each mouse tissue 
was evaluated in duplo plates to assure reproducibility.    
  Influenza virus challenge   .    Antigen-specific  CD8     +        T-cell responses 
induced by ovalbumin plasmid immunization were evaluated using the 
genetically modified influenza strain A / PR / 8 / 34 (PR8, H1N1) encoding 
the OVA  257 – 264  (SIINFEKL) K b -restricted epitope in the neuraminidase 
protein.  31   C57BL6 mice were immunized by the pulmonary route with 
PEI-DNA-OVA and 6 weeks later challenged intranasally with 10  5  EID50 
of the influenza strain.    
  Statistical analysis   .   Immune response data are presented as mean ± s.e. 
for each experimental group. Statistical analyses were performed using 
the two-sided Student ’ s  t -test or one-way analysis of variance, and  P     <     0 . 0 5  
was considered significant.        
        SUPPLEMENTARY MATERIAL   is linked to the online version of the 
paper at   http://www.nature.com/mi       
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